Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535mIpsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a Share XIpsen adds Blueprint’s FOP rare disease drug to pipeline for $535mhttps://pharmaphorum.com/news/ipsen-adds-blueprints-fop-rare-disease-drug-to-pipeline-for-535m/
Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200mTakeda is to sell off a portfolio of over-the-counter and prescription drugs in the Near East, Middle East, Share XDebt-laden Takeda to sell OTC drugs in Middle East and Africa for $200mhttps://pharmaphorum.com/news/takeda-to-sell-otc-drugs-in-middle-east-and-africa-for-200m/
Takeda breaks into top 20 largest pharmas with Shire mergerTakeda broke into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger Share XTakeda breaks into top 20 largest pharmas with Shire mergerhttps://pharmaphorum.com/news/takeda-breaks-into-top-20-largest-pharmas-with-shire-merger/
Sobi stays on its acquisitive streak with $915m Dova dealSweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover Share XSobi stays on its acquisitive streak with $915m Dova dealhttps://pharmaphorum.com/news/sobi-stays-on-its-acquisitive-streak-with-915m-dova-deal/
Takeda eyes emerging markets asset sale to trim its debt; reportTakeda is said to be considering the sale of assets in emerging markets and western Europe to pay Share XTakeda eyes emerging markets asset sale to trim its debt; reporthttps://pharmaphorum.com/news/takeda-eyes-emerging-markets-asset-sale-to-trim-its-debt-report/
Lundbeck to acquire Alder, and migraine drug, for $1.95bnLundbeck is to acquire Alder BioPharmaceuticals and its late-stage migraine drug eptinezumab in a deal worth up to Share XLundbeck to acquire Alder, and migraine drug, for $1.95bnhttps://pharmaphorum.com/news/lundbeck-to-acquire-alder-and-migraine-drug-for-1-95bn/
Unions call on US antitrust regulators to block $63 billion ‘AbbVieGan’ mergerUS antitrust authorities are coming under pressure from consumer groups and unions to block the proposed $63 billion Share XUnions call on US antitrust regulators to block $63 billion ‘AbbVieGan’ mergerhttps://pharmaphorum.com/news/unions-call-on-us-antitrust-regulators-to-block-63-billion-abbviegan-merger/
GSK buys Avalon-partnered Sitari and its coeliac drugGlaxoSmithKline’s longstanding collaboration with Avalon Ventures has resulted in a first deal – a buyout of Sitari Pharma Share XGSK buys Avalon-partnered Sitari and its coeliac drughttps://pharmaphorum.com/news/gsk-buys-avalon-partnered-sitari-and-its-coeliac-drug/
Sumitomo Dainippon bolts on pipeline via $3bn Roivant allianceVivek Ramaswamy’s Roivant group has forged its biggest and most wide-ranging alliance to date, licensing dozens of drugs Share XSumitomo Dainippon bolts on pipeline via $3bn Roivant alliancehttps://pharmaphorum.com/news/sumitomo-dainippon-bolts-on-pipeline-via-3bn-roivant-alliance/
